Skip to main content

Roivant invests 200 million dollars in Immunovant

| News

Roivant invests 200 million dollars in Immunovant

06.08.2021


The Basel-based Roivant Group has invested a total of 200 million dollars in the US biopharmaceutical company Immunovant. This investment is designed to drive forward the development of a drug to treat autoimmune diseases. Immunovant also operates a branch office in Basel.

Roivant Sciences has made a strategic investment in the amount of 200 million US dollars in Immunovant. This fresh capital injection should primarily serve to drive forward the development of the drug candidate IMVT-1401 for the treatment of various autoimmune diseases.

According to a press release, Roivant Sciences has acquired 17,021,276 ordinary shares in Immunovant at a price of 11.75 dollars per share. The investment sees the company’s stake in Immunovant increase from 57.5 percent to 63.8 percent – based on Immunovant’s cash balance and share count as of March 31, 2021.

Over the next 12 months, Immunovant intends not only to continue the existing studies in relation to IMVT-1401, but also to initiate two new clinical trials, according to comments in the press release from Peter Salzmann, CEO of Immunovant.

“We are incredibly excited about the prospects for IMVT-1401, and we are eager to support Immunovant through this investment”, says Matt Gline, CEO of Roivant Sciences, in the press release.

Roivant Sciences focuses on the development of innovative drugs in the areas of neurology, oncology, endocrinology, dermatology and hepatology. The Group’s global headquarters have been located in Basel since 2016.

Immunovant is listed on the NASDAQ-GS stock exchange in the USA and also operates a branch office in Basel.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Tenpoint aims to make vision loss reversible

The startup Tenpoint Therapeutics has started operations with a funding round of 70 million US dollars. It works to make...
Read More

Roche and ETH training the next generation of researchers

Roche, the Basel-based life sciences firm, and the Swiss Federal Institute of Technology in Zurich (ETH) are joining forces to...
Read More

Clear Solutions Labs seeks to benefit from the Basel Area

The founders of Clear Solutions Laboratories are putting together a team of experts in the fields of biotechnology, pharmaceutical science...
Read More

QuantumBasel offers access to the world’s most powerful quantum computers

QuantumBasel has consolidated its status as a neutral quantum hub with access to the world’s best quantum computers through a...
Read More

Medical informatics is shaping Switzerland’s digital future

Switzerland is at the forefront of embracing medical informatics, and innovative biotech hubs – such as the Basel Area –...
Read More

Ground-breaking oncology being developed in the Basel Area

The Basel Area – covering northwestern Switzerland – has seen tremendous growth in recent years, and has become a true...
Read More

Do you have a question? We'd like to hear from you.